

IN THE CLAIMS

Please amend claims 1-3 and add new claims 5-12 as follows:

1. (Currently amended) A method for treating a host infected with a lentivirus comprising exposing said host to a lentivirus vector and a biologically acceptable carrier, excipient and diluent, wherein the lentivirus vector has an intact 5' lentivirus LTR.
2. (Currently amended) The method of claim 1, wherein said vector has ~~an intact 5' LTR~~ a packaging signal sequence.
3. (Currently amended) The method of claim 1, wherein said lentivirus of the host infection is human immunodeficiency virus (HIV).
4. (Original) The method of claim 3, wherein said HIV is HIV-1.  
*QJ*
5. (New) The method of claim 1, wherein the lentivirus vector is derived from HIV.
6. (New) The method of claim 5, wherein the HIV is HIV-1.
7. (New) The method of claim 1, wherein the treating comprises inhibiting lentiviral replication.
8. (New) The method of claim 1, wherein the lentivirus vector has 124 base pairs of nef sequences upstream of the 3' LTR replaced with a polylinker.
9. (New) The method of claim 2, wherein the packaging signal sequence comprises the leader sequence downstream of the LTR and until the beginning of the gag gene.
10. (New) The method of claim 1, wherein the lentivirus vector includes the rev response element.

- Ad  
Ant*
- 
11. (New) The method of claim 1, wherein the lentivirus vector contains a transgene.
  12. (New) The method of claim 1, wherein the lentivirus vector lacks a transgene.